year 11, Issue 1 (March - April 2017)                   Iran J Med Microbiol 2017, 11(1): 48-57 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hosseini khomeirani S, Ma’mani L, Issazade K. Study of the antimicrobial effect of Amikacin encapsulated in Mesoporous Silica nanoparticles against Pseudomonas aeruginosa and Staphylococcus aureus. Iran J Med Microbiol. 2017; 11 (1) :48-57
1- Department of Microbiology, Rasht Branch, Islamic Azad University, Rasht, Iran ,
2- Department of Nanotechnology, Agricultural Biotechnology Research Institute of Iran (ABRII), Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran.
3- Department of Microbiology, Lahijan Branch, Islamic Azad University, Lahijan, Iran
Abstract:   (6863 Views)

Background and Aim: Amikacin, as an aminoglycoside antibiotic, is prescribed against a broad spectrum of bacteria. Limiting the use of this medicine includes the risk of microbial resistance, toxicity and short half-life in the body. One strategy to overcome the problem is the use of nanotechnology which can help to development of medicine delivery systems. This study was done in 2015 to assess the ability of mesoporous silica nanoparticles in improving the traditional formulation of amikacin.

Materials and Methods: SBA-15 was synthesized using hydrothermal method. The kinetics of medicine release from carriers, was investigated at 37 °C. The antimicrobial activity of formulations was conducted by disk diffusion method and broth dilution test on samples of bacteria.

Results: Nanoparticles SBA-15 with a hexagonal arrangement and pore diameter of
5 -100 nm, were able to encapsulation 47% of Amikacin. The kinetics of medicine release from the carrier at pH (5, 7.4and 8.9) showed that in the first 24 hours, respectively, 10, 34.54 and 69% amikacin was released from the carriers. The rate of MIC of native amikacin and amikacin@SBA-15 of S. aureus were respectively, 1.66, 13.29 μg/mL and for P. aeruginosa were respectively 3.32, 26.59 μg/mL.

Conclusions: The results confirmed the stability of the encapsulated amikacin and high capacity SBA-15 to control the medicine release in the acidic environment of the stomach to the intestinal alkaline that made hopes to provide oral formulation of the medicine.

Full-Text [PDF 1008 kb]   (1481 Downloads)    
Type of Study: Original | Subject: Nanotechnology In Medicine
Received: 2016/06/13 | Accepted: 2016/10/26 | ePublished: 2017/03/16

1. Goodman & Gilman's: Chapter 54: Aminoglycosides. In: Laurence L. Brunton, Bruce A. Chabner, Björn C. Knollmann ,editors. The Pharmacological Basis of Therapeutics. 12e. New York: McGraw-Hill; 2011.p1507–1517.
2. Yonova D, Vazelov E, Papazov V, Trendafilov I, Simeonov A. Amikacin-treatment of an urinary tract infection in a hemodialysis patient-what may be eventualy missed?. Hippokratia. 2006;10(1):39-40. [Article]
3. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of aminoglycoside and β-lactam combination therapy versus β-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clinical infectious diseases. 2005;41(2):149-58. [Article] [PubMed]
4. Hinz A, Lee S, Jacoby K, Manoil C. Membrane proteases and aminoglycoside antibiotic resistance. Journal of bacteriology. 2011;193(18):4790-7. [PubMed]
5. Losa C, Calvo P, Castro E, Vila‐Jato JL, Alonso MJ. Improvement of ocular penetration of amikacin sulphate by association to poly (butylcyanoacrylate) nanoparticles. Journal of pharmacy and pharmacology. 1991;43(8):548-52. [PubMed]
6. Barrera V, Sinues B, Martinez P, Buatas A, Pinero A. Penetration of amikacin into the anterior chamber of the human eye. Journal francais d'ophtalmologie. 1983;7(8-9):539-43. [PubMed]
7. Krasemann C, Mester U, Stein HJ. Experimental studies on topic application of amikacin to the eye (author's transl). Arzneimittel-Forschung. 1977;28(9):1602-4.
8. Gonzalez 3rd LS, Spencer JP. Aminoglycosides: a practical review. American family physician. 1998; 58(8):1811-20. [PubMed]
9. Pagkalis S, Mantadakis E, Mavros MN, Ammari C, Falagas ME. Pharmacological considerations for the proper clinical use of aminoglycosides. Drugs. 2011;71(17):2277-94. [PubMed]
10. Boyer A, Gruson D, Bouchet S, Clouzeau B, Hoang-Nam B, Vargas F, Gilles H, Molimard M, Rogues AM, Moore N. Aminoglycosides in septic shock. Drug safety. 2013; 36(4):217-30. [PubMed]
11. Croes S, Koop AH, van Gils SA, Neef C. Efficacy, nephrotoxicity and ototoxicity of aminoglycosides, mathematically modelled for modelling-supported therapeutic drug monitoring. European Journal of Pharmaceutical Sciences. 2012; 45(1):90-100. [PubMed]
12. Huth ME, Ricci AJ, Cheng AG. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. International journal of otolaryngology. 2011;2011. [PubMed]
13. Bodem CR, Lampton LM, Miller DP, Tarka EF, Everett ED. Endobronchial pH: Relevance to Aminoglycoside Activity in Gram-Negative Bacillary Pneumonia 1, 2. American Review of Respiratory Disease. 1983;127(1):39-41. [Article]
14. Mugabe C, Azghani AO, Omri A. Preparation and characterization of dehydration–rehydration vesicles loaded with aminoglycoside and macrolide antibiotics. International journal of pharmaceutics. 2006; 307(2):244-50. [PubMed]
15. Mirzaee M, Owlia P, Mehrabi MR. Comparison of the bactericidal activity of amikacin in free and liposomal formulation against gram-negative and gram-positive bacteria. Jundishapur Journal of Natural Pharmaceutical Products. 2009; 4(1):1-7. [Article]
16. Lee JH, Cheng KT, Malinin V, Li Z, Yao Z, Lee SJ, Gould CM, Olivier KN, Chen C, Perkins WR, Paik CH. 99mTc-labeled therapeutic inhaled amikacin loaded liposomes. Journal of liposome research. 2013; 23(4):336-42. [PubMed]
17. Ghaffari S, Varshosaz J, Saadat A, Atyabi F. Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles. International journal of nanomedicine. 2011; 6:35. [PubMed]
18. Varshosaz J, Ghaffari S, Khoshayand MR, Atyabi F, Dehkordi AJ, Kobarfard F. Optimization of freeze-drying condition of amikacin solid lipid nanoparticles using D-optimal experimental design. Pharmaceutical development and technology. 2012; 17(2):187-94. [PubMed]
19. Varshosaz J, Ghaffari S, Mirshojaei SF, Jafarian A, Atyabi F, Kobarfard F, Azarmi S. Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery. BioMed research international. 2013; Article ID 136859. [Article]
20. Berger D, Bajenaru L, Nastase S, Mitran RA, Munteanu C, Matei C. Influence of structural, textural and surface properties of mesostructured silica and aluminosilicate carriers on aminoglycoside uptake and in vitro delivery. Microporous and Mesoporous Materials. 2015; 206:150-60. [PubMed]
21. Adibkia K, Barzegar-Jalali M, Javadzadeh Y, Bayrami R, Mohammadi G. A review on the porous adsorbents in drug delivery systems. Pharmaceutical Sciences. 2012; 18(2):103-18. [Article]
22. Kaukonen AM, Laitinen L, Salonen J, Tuura J, Heikkilä T, Limnell T, Hirvonen J, Lehto VP. Enhanced in vitro permeation of furosemide loaded into thermally carbonized mesoporous silicon (TCPSi) microparticles. European journal of pharmaceutics and biopharmaceutics. 2007; 66(3):348-56. [Article]
23. Slowing II, Trewyn BG, Giri S, Lin VY. Mesoporous silica nanoparticles for drug delivery and biosensing applications. Advanced Functional Materials. 2007; 17(8):1225-36. [Article]
24. Slowing II, Vivero-Escoto JL, Wu CW, Lin VS. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Advanced drug delivery reviews. 2008; 60(11):1278-88. [PubMed]
25. Park SY, Pendleton P. Mesoporous silica SBA-15 for natural antimicrobial delivery. Powder technology. 2012; 223:77-82. [Article]
26. Mohseni M, Gilani K, Mortazavi SA. Preparation and characterization of rifampin loaded mesoporous silica nanoparticles as a potential system for pulmonary drug delivery. Iranian Journal of Pharmaceutical Research. 2015; 14(1):27-34. [PubMed]
27. Nastase S, Bajenaru L, Matei C, Mitran RA, Berger D. Ordered mesoporous silica and aluminosilicate-type matrix for amikacin delivery systems. Microporous and Mesoporous Materials. 2013; 182:32-9. [PubMed]
28. Berger D, Nastase S, Mitran RA, Petrescu M, Vasile E, Matei C, Negreanu-Pirjol T. Mesostructured silica and aluminosilicate carriers for oxytetracycline delivery systems. International journal of pharmaceutics. 2016; 510(2):524-31. [PubMed]
29. Khatibi A, Ma’mani L, Khodarahmi R, Shafiee A, Maghami P, Ahmad F, Sheibani N, Moosavi-Movahedi AA. Enhancement of thermal reversibility and stability of human carbonic anhydrase II by mesoporous nanoparticles. International journal of biological macromolecules. 2015; 75:67-72. [PubMed]
30. National Committee for Clinical Laboratory Standards. 2006. Performances standard for antimicrobial susceptibility testing; 16th. Informational supplement. M100-S16. National Committee for Clinical Laboratory Standards,Wayne, Pa.
31. Sailaja AK, Amareshwar P, Chakravarty P. Formulation of solid lipid nanoparticles and their applications. Current Pharma Res. 2011; 1(2):97-203.
32. Ekambaram P, Sathali AA, Priyanka K. Solid lipid nanoparticles: a review. Scientific reviews and chemical communications. 2012; 2(1): 80-102 [Article]
33. Zhao D, Feng J, Huo Q, Melosh N, Fredrickson GH, Chmelka BF, Stucky GD. Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores. science. 1998; 279(5350):548-52. [PubMed]
34. Zhao D, Yang P, Melosh N, Feng J, Chmelka BF, Stucky GD. Continuous mesoporous silica films with highly ordered large pore structures. Advanced Materials. 1998; 10(16):1380-5. [Article]

Add your comments about this article : Your username or Email:

Send email to the article author

© 2020 All Rights Reserved | Iranian Journal of Medical Microbiology

Designed & Developed by : Yektaweb | Publisher: Farname Inc